Summary
This preprint reports findings from a population-based survey in Great Britain examining how many adults are currently using GLP-1 receptor agonists for weight loss and how many would consider doing so. The study likely provides nationally representative estimates and explores inequalities in access or interest across demographic groups. Given the rapid uptake of these medications, the findings offer timely evidence to inform public health planning and NHS prescribing policy.
UK applicability
The study is conducted entirely within Great Britain, making its findings directly applicable to NHS policy, prescribing frameworks, and public health strategy in England, Scotland, and Wales. The findings are particularly relevant given ongoing NICE guidance on GLP-1 agonists and NHS England's weight management commissioning priorities.
Key measures
Prevalence of GLP-1 receptor agonist use (%); prevalence of interest in use (%); sociodemographic correlates of use and interest
Outcomes reported
The study estimated the proportion of the Great British population currently using GLP-1 receptor agonists (such as semaglutide or liraglutide) for weight loss, as well as the proportion expressing interest in using them. It likely examined variation by sociodemographic characteristics such as age, sex, BMI, and socioeconomic status.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.